Blood Plasma Articles & Analysis
30 news found
The testing works by isolating cell-free DNA (cfDNA) from blood plasma to uncover circulating tumor DNA (ctDNA). Isolating these DNA samples from a simple blood draw is less invasive than a traditional biopsy, helping to simplify patient monitoring and more quickly guide clinical decision-making. ...
Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA (ctDNA). This non-invasive testing allows for cancer genomic profiling and disease monitoring. ...
MM accounts for 10% of hematological malignancies and has a current worldwide incidence level of 160,0002. This type of blood cancer forms in plasma cells (PCs) located in the bone marrow (BM). ...
Subjects were randomized into one of two sequences (a fasted state, and a fed state [after a high-fat test meal]) and dosed with a 25mg dose of CTx-1301 The primary PK endpoints were maximum concentration (expressed as Cmax) during the first 28 hours after dosing, and the total amount of the active pharmaceutical ingredient (API), dexmethylphenidate, in the blood (expressed as ...
Key differentiators noted by the authors include faster turn-around time (< 20 minutes), ease of use (tested directly from whole blood, without need for significant laboratory infrastructure) and analytical precision, as noted below. ...
The primary objective is to evaluate the absorption of buspirone and the presence of metabolite 1-pyrimidinylpiperazine (1-PP) in blood plasma from time delayed formulations and correlate with scintigraphic time and site of release. ...
“With patient enrollment complete and data analysis underway, we aim to show that the implications of COVID as an endothelial disease utilizing this measure along with precise measurement of total blood, red cell and plasma volume could help guide the care of COVID-19 patients, thus promoting better treatment of these ...
The study, titled “Blood volume and albumin transudation in critically-ill COVID-19 patients,” showed that COVID-19 patients suffer from significant capillary damage and blood volume deficits that care teams became aware of only through the use of the Daxor BVA-100 blood test. ...
” In heart failure, physicians seek to optimize a patient’s blood volume which has wide variations in total blood volume (TBV), plasma volume (PV) and red blood cell volume (RBCV). ...
SAGAsafe® is a patented improvement of digital PCR that enables approximately 100-fold increased sensitivity compared to competitor methods, and can be used to quantify sequence variants in tissue samples as well as liquid biopsies such as blood plasma with unprecedented performance. SAGAsafe® is part of a portfolio of ultrasensitive technologies, which ...
” In addition, The Journal of the American Medical Association Neurology published findings from BioFINDER’s large comparison of blood plasma amyloid-beta assays. One of the types of assays included in the study was the liquid chromatography–mass spectrometry (LC-MS/MS) assay that Dr. ...
C2N under a technology transfer agreement with Washington University, developed this mass spec assay into the PrecivityAD™ blood test. BioFINDER’s large comparison of blood plasma amyloid-beta assays found that the Washington University assay performed the best out of seven assays, including in the measurement of phosphorylated ...
SAGAsafe is a patented improvement of digital PCR that enables approximately 100-fold increased sensitivity compared to competitor methods, and can be used to quantify mutations in tissue samples as well as liquid biopsies such as blood plasma with unprecedented performance. The analyses will be run in the SAGA Diagnostics central laboratory in Lund, Sweden. ...
No other critical care blood gas analyzer has this unique capability. Low MCHC, associated with hypochromic anemias, can indicate internal bleeding, anemia of chronic disease, chronic low grade blood loss, iron deficiency, and thalassemia. ...
Abecma® (idecabtagene vicleucel; ide-cel) is a chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of certain adult patients with relapsed or refractory multiple myeloma, a blood cancer formed by malignant plasma cells and typically originating in the bone marrow. ...
Latvian COVID-19 cohort includes various types of samples (blood, serum, plasma, oropharyngeal swabs, PBMC, feces, urine, isolated DNA, RNA), molecular data (blood biochemistry, cytokine panel, genome-wide genotyping, viral genome data, metagenome, metabolome, and transcriptome data) as well as excessive characterization of each clinical case. ...
This assay aims to provide deep analysis of the human plasma proteome for detection and characterization of novel prostate cancer biomarkers. ...
The test detects specific SARS CoV2 IgG and IgM antibodies in the blood in response to a coronavirus infection. The detection of antibodies can be used to identify those who have already had contact with the virus. ...
DiamiR, a developer of innovative blood-based diagnostic tests for neurodegenerative and other diseases, today announced that it has received a notice of allowance from the United States Patent & Trademark Office (USPTO) for U.S. ...
ByDiamiR
Several governments around the world, including the U.S. and Spain, consider Grifols’ manufacturing plants and plasma-and blood-donation centers as essential infrastructures. For this reason, the donors and personnel that make these donations possible are exempt when restrictions are placed on movement. Over the last years, Grifols invested heavily to ...